TOFA suppresses ovarian cancer cell growth in vitro and in vivo
- PMID: 23732836
- DOI: 10.3892/mmr.2013.1505
TOFA suppresses ovarian cancer cell growth in vitro and in vivo
Abstract
A characteristic feature of cancer cells is the activation of de novo fatty acid synthesis. Acetyl‑CoA carboxylase (ACC) is a key enzyme in fatty acid synthesis, accelerating the reaction that carboxylates cytosolic acetyl‑CoA to form malonyl‑CoA. ACC is highly expressed in several types of human cancer and is important in breast and prostate cancer cell growth. The aim of the present study was to investigate the effects of 5‑tetradecyloxy‑2‑furoic acid (TOFA), an allosteric inhibitor of ACC, on the proliferation and cell cycle progression of the ovarian cancer cell lines COC1 and COC1/DDP. TOFA was found to be cytotoxic to COC1 and COC1/DDP cells with a 50% inhibitory concentration (IC50) of ~26.1 and 11.6 µg/ml, respectively. TOFA inhibited the proliferation of the cancer cells examined in a time‑ and dose‑dependent manner, arrested the cells in the G0/G1 cell cycle phase and induced apoptosis. The expression of the cell cycle regulating proteins cyclin D1 and cyclin-dependent kinase (CDK) 4, as well as the expression of the apoptosis‑related proteins caspase‑3 and Bcl‑2, were detected by western blot analysis. Cyclin D1, CDK4 and Bcl‑2 protein expression was inhibited by TOFA, while caspase‑3 was cleaved and activated. To the best of our knowledge, the present study demonstrated for the first time that TOFA inhibits COC1/DDP cell growth in ovarian tumor mouse xenografts. By inhibiting ACC, TOFA may be a promising small molecule agent for ovarian cancer therapy.
Similar articles
-
Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells.Cancer Res. 2007 Apr 1;67(7):2964-71. doi: 10.1158/0008-5472.CAN-06-3439. Cancer Res. 2007. PMID: 17409402
-
Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.Oncol Rep. 2004 Dec;12(6):1365-70. Oncol Rep. 2004. PMID: 15547764
-
Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells.Cancer Res. 2003 Nov 1;63(21):7330-7. Cancer Res. 2003. PMID: 14612531
-
[Role of apoptosis-associated genes and caspase-3 in cisplatin-resistant human ovarian cancer cell lines].Zhonghua Fu Chan Ke Za Zhi. 2003 Mar;38(3):158-61. Zhonghua Fu Chan Ke Za Zhi. 2003. PMID: 12816691 Chinese.
-
The acetyl-CoA carboxylase enzyme: a target for cancer therapy?Expert Rev Anticancer Ther. 2015 Jun;15(6):667-76. doi: 10.1586/14737140.2015.1038246. Epub 2015 May 15. Expert Rev Anticancer Ther. 2015. PMID: 25979092 Review.
Cited by
-
How cancer cells remodel lipid metabolism: strategies targeting transcription factors.Lipids Health Dis. 2021 Nov 14;20(1):163. doi: 10.1186/s12944-021-01593-8. Lipids Health Dis. 2021. PMID: 34775964 Free PMC article. Review.
-
Lipogenesis inhibitors: therapeutic opportunities and challenges.Nat Rev Drug Discov. 2022 Apr;21(4):283-305. doi: 10.1038/s41573-021-00367-2. Epub 2022 Jan 14. Nat Rev Drug Discov. 2022. PMID: 35031766 Free PMC article. Review.
-
Lipid Metabolism in Oncology: Why It Matters, How to Research, and How to Treat.Cancers (Basel). 2021 Jan 26;13(3):474. doi: 10.3390/cancers13030474. Cancers (Basel). 2021. PMID: 33530546 Free PMC article. Review.
-
Lipid Regulatory Proteins as Potential Therapeutic Targets for Ovarian Cancer in Obese Women.Cancers (Basel). 2020 Nov 21;12(11):3469. doi: 10.3390/cancers12113469. Cancers (Basel). 2020. PMID: 33233362 Free PMC article. Review.
-
Specific Effects of Trabectedin and Lurbinectedin on Human Macrophage Function and Fate-Novel Insights.Cancers (Basel). 2020 Oct 20;12(10):3060. doi: 10.3390/cancers12103060. Cancers (Basel). 2020. PMID: 33092171 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials